Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures growth accelerates

Q3 FY2026 capital expenditures of $1.67M (cash outflow) rose 278.9% year over year, ahead of the +241.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 47.6% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Capital expenditures amounted to 180.9% of revenue in FY2025, up 153.6 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +278.9% holds above the trailing-twelve-month pace of +241.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.67M-47.6% QoQ
Last fiscal yearDec 2025
-$2.71M+41.4% YoY
LTMSep 2026
-$7.48M+241.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+278.9%——
1 year+41.4%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(2.71M) USD
Year-over-year change
-41.4%

Capital Expenditures vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 capital expenditures of $7.48M is the 3rd largest of the 10 companies compared; the peer median is $1M.
  • Its year-over-year change of +241.6% is the highest of 8, against a peer median of -37.7%.
  • Capital expenditures amounts to 6676.8% of revenue for CLDX, versus a peer median of 1.1%.
CLDX Competitors Peer median
Capital Expenditures for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$9.67M +36.9%+239.3%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$9.5M -13.4%+4.6%1.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$7.48M +241.6%+14.1%6676.8%
XNCRXencor, Inc.LTM Jun 2026$2.47M -62.7%-58.3%2.4%
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M -37.7%-19.2%1.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$1M -66.7%-30.7%0.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$89K +43.5%-51.0%—
ADAGAdagene Inc.LTM Jun 2024$12.55K —-70.9%1.5%
AGENAgenus Inc.LTM Mar 2026$1K -99.8%-77.9%0.0%
CGENCompugen Ltd.LTM Dec 2025$0 —-14.3%0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $1M-37.7%-30.7%1.1%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.76M)
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
Deferred Income Tax(227K)0000
Stock-Based Compensation8.95M023.89M34.24M36.22M
Change in Working Capital(1.05M)(3.9M)13.46M(21.6M)14.06M
Accounts Receivables1.57M(175K)(2.28M)1.93M(1.32M)
Inventory00000
Accounts Payables3.65M3.12M9.38M11.63M11.03M
Other Working Capital(6.28M)(6.85M)6.36M(35.16M)4.34M
Other Non-Cash Items(1.14M)9.6M(6.22M)(15.73M)(5.84M)
Operating Cash Flow(60.91M)(103.73M)(107.29M)(157.78M)(210.95M)
Capital Expenditures(1.25M)(1.83M)(1.82M)(1.92M)(2.71M)
Acquisitions (Net)27K69K000
Purchases of Investments(389.88M)(188.97M)(424.56M)(789.92M)(384.5M)
Sales of Investments174.95M280.67M320.6M501.71M596.29M
Other Investing Activities00000
Investing Cash Flow(216.16M)89.94M(105.78M)(290.13M)209.07M
Debt Repayment00000
Common Stock Issued269.89M4.08M216.22M432.3M2.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.48M02.24M9.15M0
Financing Cash Flow272.37M4.08M218.46M441.45M2.39M
Effect of Forex Changes00000
Net Change in Cash(4.69M)(9.71M)5.39M(6.46M)515K
Free Cash Flow(62.16M)(105.56M)(109.11M)(159.7M)(213.66M)

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.